Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gineyts, E.
Right arrow Articles by Delmas, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gineyts, E.
Right arrow Articles by Delmas, P. D.
Related Collections
Right arrow Diagnostics and Imaging Procedures
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 315-323
© 2001 British Society for Rheumatology

Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation

E. Gineyts, P. Garnero1 and P. D. Delmas

INSERM Research Unit 403, Hôpital Herriot, Lyon and
1 SYNARC, Lyon, France

Objective. Glucosyl-galactosyl pyridinoline (Glc-Gal-PYD), which has been identified in urine, is a glycosylated analogue of pyridinoline. The tissue distribution of this molecule has not been yet determined and its utility as a potential biochemical marker of joint degradation in patients with joint diseases has not been investigated.

Methods and results. In this study, we demonstrate that Glc-Gal-PYD is abundant in human synovium tissue, absent from bone and present in minute amounts in cartilage and other soft tissues, such as muscle and liver. Using an ex vivo model of human joint tissue degradation, we found that Glc-Gal-PYD is released from synovium tissue, but not from bone and cartilage. The urinary level of Glc-Gal-PYD was increased by 109% in patients with rheumatoid arthritis (RA) compared with healthy adults, but was normal in patients with Paget's disease of bone. In addition, Glc-Gal-PYD was higher in those patients with destructive disease, as assessed by X-rays of the joints, than in those with non-destructive RA.

Conclusion. Glc-Gal-PYD may be useful for the clinical investigation of patients with joint disease.

KEY WORDS: Synovium, Cartilage, Bone, Rheumatoid arthritis, Osteoarthritis, Pyridinoline, Glycosylation, Collagen.

Correspondence to: E. Gineyts, INSERM U403, Hôpital E. Herriot, pavillon F, place d'Arsonval, 69437 Lyon cedex 03, France


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
E Gineyts, J A Mo, A Ko, D B Henriksen, S P Curtis, B J Gertz, P Garnero, and P D Delmas
Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis
Ann Rheum Dis, July 1, 2004; 63(7): 857 - 861.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.